Expanding the therapeutic armamentarium in decompensated heart failure: Using intravenous fenoldopam

Congestive Heart Failure

Volumn 7, Issue 1, 2001, Pages 51-52+56

  Potluri, S ^a   Uber, P ^a   Mehra, M R ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; DOXORUBICIN; FENOLDOPAM; MILRINONE; TORASEMIDE;

ADULT; ARTICLE; CARDIOMYOPATHY; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART FAILURE; HUMAN; PULMONARY HYPERTENSION; TITRIMETRY;

EID: 0035121664     PISSN: 10797998     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Pulmonary vascular resistance and the risk of heart transplantation
2. Vasodilator therapy after heart transplantation: Effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin EI, and sodium nitroprusside
3. Selective and nonselective dopamine receptor agonists: An innovative approach to cardiovascular disease treatment
4. Localization of dopamine D1 and D2 receptor mRNAs in the rat systemic and pulmonary vasculatures
5. Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension
6. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects
7. Functional ontogeny of pulmonary, vascular DAI dopamine receptors in the isolated perfused rabbit lung
8. Stimulation of the dopamine I receptor increases lung edema clearance
9. Hemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure
10. Intravenous fenoldopam in heart failure: Comparing the hemodynamic effects of dopamine I receptor agonism with nitroprusside
11. Comparative effects of fenoldopam mesylate and nitroprusside on left ventricular performance in severe systemic hypertension
12. Hemodynamic, renal and neurohumoral effects of a selective oral DAI receptor agonist (fenoldopam) in patients with congestive heart failure